Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 1
2018 2
2020 1
2021 8
2022 10
2023 14
2024 16
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for athira one an
Search for Athita Onuean instead (1 results)
Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease.
Vitek GE, Decourt B, Sabbagh MN. Vitek GE, et al. Expert Opin Investig Drugs. 2023 Feb;32(2):89-94. doi: 10.1080/13543784.2023.2178414. Epub 2023 Feb 28. Expert Opin Investig Drugs. 2023. PMID: 36749830 Free PMC article. Review.
The experience of aducanumab informs the development of other mAbs, such as lecanemab. One consideration is the conformation of Abeta targets. Targeting monomeric species has not resulted in robust clinical efficacy, whereas targeting Abeta in the form of oligomers, protof …
The experience of aducanumab informs the development of other mAbs, such as lecanemab. One consideration is the conformation of Abeta …
Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.
Honig LS, Sabbagh MN, van Dyck CH, Sperling RA, Hersch S, Matta A, Giorgi L, Gee M, Kanekiyo M, Li D, Purcell D, Dhadda S, Irizarry M, Kramer L. Honig LS, et al. Alzheimers Res Ther. 2024 May 10;16(1):105. doi: 10.1186/s13195-024-01441-8. Alzheimers Res Ther. 2024. PMID: 38730496 Free PMC article. Clinical Trial.
RESULTS: Overall, 1795 participants from Core and 1612 participants with at least one dose of lecanemab (Core + OLE) were included. Lecanemab was generally well-tolerated in Clarity AD, with no deaths related to lecanemab in the Core study. ...
RESULTS: Overall, 1795 participants from Core and 1612 participants with at least one dose of lecanemab (Core + OLE) were included. L …
Results and insights from a phase I clinical trial of Lomecel-B for Alzheimer's disease.
Brody M, Agronin M, Herskowitz BJ, Bookheimer SY, Small GW, Hitchinson B, Ramdas K, Wishard T, McInerney KF, Vellas B, Sierra F, Jiang Z, Mcclain-Moss L, Perez C, Fuquay A, Rodriguez S, Hare JM, Oliva AA Jr, Baumel B. Brody M, et al. Alzheimers Dement. 2023 Jan;19(1):261-273. doi: 10.1002/alz.12651. Epub 2022 Mar 31. Alzheimers Dement. 2023. PMID: 35357079 Free PMC article. Clinical Trial.
Tilavonemab in early Alzheimer's disease: results from a phase 2, randomized, double-blind study.
Florian H, Wang D, Arnold SE, Boada M, Guo Q, Jin Z, Zheng H, Fisseha N, Kalluri HV, Rendenbach-Mueller B, Budur K, Gold M. Florian H, et al. Brain. 2023 Jun 1;146(6):2275-2284. doi: 10.1093/brain/awad024. Brain. 2023. PMID: 36730056 Free PMC article. Clinical Trial.
In this 96-week, randomized, double-blind, placebo-controlled study (NCT02880956), patients aged 55-85 years meeting clinical criteria for early Alzheimer's disease with a Clinical Dementia Rating-Global Score of 0.5, a Mini-Mental State Examination score of 22 to 30, a Repeatabl …
In this 96-week, randomized, double-blind, placebo-controlled study (NCT02880956), patients aged 55-85 years meeting clinical criteria for e …
One step forward to personalized medicine?
Dodge HH, Arnold SE. Dodge HH, et al. Alzheimers Dement (N Y). 2023 Nov 15;9(4):e12435. doi: 10.1002/trc2.12435. eCollection 2023 Oct-Dec. Alzheimers Dement (N Y). 2023. PMID: 38023621 Free PMC article. No abstract available.
Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial.
Mintzer J, Lanctôt KL, Scherer RW, Rosenberg PB, Herrmann N, van Dyck CH, Padala PR, Brawman-Mintzer O, Porsteinsson AP, Lerner AJ, Craft S, Levey AI, Burke W, Perin J, Shade D; ADMET 2 Research Group. Mintzer J, et al. JAMA Neurol. 2021 Nov 1;78(11):1324-1332. doi: 10.1001/jamaneurol.2021.3356. JAMA Neurol. 2021. PMID: 34570180 Free PMC article. Clinical Trial.
IMPORTANCE: Apathy, characterized by diminished will or initiative and one of the most prevalent neuropsychiatric symptoms in individuals with Alzheimer disease, is associated with significant caregiver burden, excess disability, increased medical costs, and mortality. ...
IMPORTANCE: Apathy, characterized by diminished will or initiative and one of the most prevalent neuropsychiatric symptoms in individ …
Brexpiprazole for Agitation Associated With Dementia Due to Alzheimer's Disease.
Lee D, Clark ED, Antonsdottir IM, Porsteinsson AP. Lee D, et al. J Am Med Dir Assoc. 2024 Oct;25(10):105173. doi: 10.1016/j.jamda.2024.105173. Epub 2024 Jul 22. J Am Med Dir Assoc. 2024. PMID: 39053890 Review.
Nearly all patients with AD develop neuropsychiatric symptoms (NPSs). Agitation is one of the most distressing and challenging NPS. Brexpiprazole is an oral antipsychotic and is the first approved pharmacologic agent in the United States for the treatment of agitation asso …
Nearly all patients with AD develop neuropsychiatric symptoms (NPSs). Agitation is one of the most distressing and challenging NPS. B …
Pharmacotherapies for the Treatment of Progressive Supranuclear Palsy: A Narrative Review.
Dunning EE, Decourt B, Zawia NH, Shill HA, Sabbagh MN. Dunning EE, et al. Neurol Ther. 2024 Aug;13(4):975-1013. doi: 10.1007/s40120-024-00614-9. Epub 2024 May 14. Neurol Ther. 2024. PMID: 38743312 Free PMC article. Review.
Progressive supranuclear palsy (PSP) is a neurodegenerative disorder resulting from the deposition of misfolded and neurotoxic forms of tau protein in specific areas of the midbrain, basal ganglia, and cortex. It is one of the most representative forms of tauopathy. PSP pr …
Progressive supranuclear palsy (PSP) is a neurodegenerative disorder resulting from the deposition of misfolded and neurotoxic forms of tau …
Fosgonimeton attenuates amyloid-beta toxicity in preclinical models of Alzheimer's disease.
Reda SM, Setti SE, Berthiaume AA, Wu W, Taylor RW, Johnston JL, Stein LR, Moebius HJ, Church KJ. Reda SM, et al. Neurotherapeutics. 2024 Jul;21(4):e00350. doi: 10.1016/j.neurot.2024.e00350. Epub 2024 Apr 9. Neurotherapeutics. 2024. PMID: 38599894 Free PMC article.
Following Abeta injury, fosgo-AM significantly enhanced activation of pro-survival effectors ERK and AKT, and reduced activity of GSK3beta, one of the main kinases involved in tau hyperphosphorylation. Fosgo-AM also mitigated Abeta-induced deficits in Unc-like kinase 1 (UL …
Following Abeta injury, fosgo-AM significantly enhanced activation of pro-survival effectors ERK and AKT, and reduced activity of GSK3beta, …
Roadmap for C9ORF72 in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis: Report on the C9ORF72 FTD/ALS Summit.
Sattler R, Traynor BJ, Robertson J, Van Den Bosch L, Barmada SJ, Svendsen CN, Disney MD, Gendron TF, Wong PC, Turner MR, Boxer A, Babu S, Benatar M, Kurnellas M, Rohrer JD, Donnelly CJ, Bustos LM, Van Keuren-Jensen K, Dacks PA, Sabbagh MN; Attendees of the inaugural C9ORF72 FTD/ALS Summit. Sattler R, et al. Neurol Ther. 2023 Dec;12(6):1821-1843. doi: 10.1007/s40120-023-00548-8. Epub 2023 Oct 17. Neurol Ther. 2023. PMID: 37847372 Free PMC article.
Some people who have the disease frontotemporal dementia or the disease amyotrophic lateral sclerosis have a change in one of their genes; the name of the gene is C9ORF72. People who carry this genetic difference usually inherited it from a parent. ...
Some people who have the disease frontotemporal dementia or the disease amyotrophic lateral sclerosis have a change in one of their g …
53 results